Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3824227 | 0.81 | KDM4E (0.69) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL31418070 | 0.81 | KDM4E (1.00) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL758123 | 0.81 | KDM4E (1.00) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL19688299 | 0.80 | POLB (0.72) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL1502785 | 0.79 | CYP1A2 (0.72) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL15228268 | 0.79 | PKM (0.67) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL6361404 | 0.79 | PKM (0.71) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL31533961 | 0.79 | PKM (0.67) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL4015033 | 0.77 | PKM (0.65) | KDM4ESMN1; SMN2PKMPOLBNPC1 | |
| SCHEMBL10601344 | 0.77 | KDM4E (0.63) | KDM4ESMN1; SMN2PKMPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-07-17 | — | — | US | disclosed |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-12 | — | — | US | disclosed |
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
| EP-3575288-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-10-27 | — | — | EP | disclosed |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676460-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3575288-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2019-12-04 | — | — | EP | disclosed |
| EP-3124475-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-08-07 | — | — | EP | disclosed |
| US-20190144426-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-05-16 | — | — | US | disclosed |
| US-9822096-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-21 | — | — | US | disclosed |
| EP-3124475-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160362396-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-15 | — | — | US | disclosed |
| EP-2473487-B1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9458114-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575184-B2 | Quinazolines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTON-MYERS SQUIBB COMPANY (US) | 2012-09-13 | — | — | US | disclosed |
| EP-2473487-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-07-11 | — | — | EP | disclosed |
| WO-2011028741-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324836-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-20250230144-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-10676460-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-20200255407-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-20160362396-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-20120232068-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNH3, KCNQ4 | KDM4E 926/4885SMN1; SMN2 3227/4885PKM 1148/4885 |
| US-11008306-B2 | Quinazolines as potassium ion channel inhibitors | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-20190144426-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-20140031345-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
| US-20230322726-A1 | QUINAZOLINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNK4, KCNQ4 | KDM4E 882/4885SMN1; SMN2 3165/4885PKM 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.